U.S. stock night trading volatility: Analyst downgrades rating causing Inhibrx stock price to drop 3.89% in after-hours trading, increasing market volatility risk

U.S. Stock Night Market Movements Inhibrx fell 3.89% in the night market. Based on recent key news: On October 27, analysts downgraded Inhibrx's rating to "Sell," believing that the stock price will be highly volatile in the next 3 to 6 months, with risks outweighing opportunities. Analysts pointed out that although the company's pipeline and operational efficiency are good, investments should be approached with caution before commercialization. This news led to a 3.89% drop in stock price. Source: Simply Wall St There have been no other significant news recently. Market volatility has increased, and risks need to be monitored. Stocks with High Trading Volume in the Industry Intellia Therapeutics rose 4.80% in the night market. Based on recent key news: On October 27, Intellia Therapeutics paused patient dosing in the MAGNITUDE and MAGNITUDE-2 trials due to a serious liver issue in one patient. This move caused the stock price to plummet by 43.3%. Source: Reuters On October 28, B of A Securities lowered Intellia Therapeutics' target price from $36 to $30, reflecting market concerns about its financial performance. Source: Benzinga On October 27, analyst Mani Foroohar maintained a Buy rating, stating that despite safety issues, the company's innovative CRISPR-Cas9 therapy remains a growth driver. Source: H.C. Wainwright. The gene editing industry faces safety challenges, with significant capital inflows. Recursion fell 0.95% in the night market. Based on recent key news: On October 24, Recursion Pharmaceuticals' CEO Christopher Gibson sold company common stock, raising market concerns about internal confidence, leading to a drop in stock price. This information was disclosed by the company through the EDGAR system. On October 26, MarketBeat analysts did not include Recursion Pharmaceuticals in their recommended buy list, despite its Hold rating, indicating insufficient market confidence in the stock, further impacting its price. Recent analyst forecasts and historical data analysis have failed to provide a positive outlook. Simply Wall St's analysis emphasized a long-term data-driven perspective but did not consider the latest company announcements, leading investors to adopt a wait-and-see attitude. Recent U.S. stock market volatility has increased, and industry dynamics need to be monitored. Moderna fell 0.64% in the night market. Based on recent key news: On October 27, Moderna announced that its mRNA-1647 vaccine study in bone marrow transplant patients will continue, although trial failures will not affect financial expectations for 2025. The company expects limited initial revenue contributions from the vaccine, which slightly impacted the stock price Source: Zhitong Finance On October 27, Moderna stated that the potential of its vaccine mRNA-1647 in high-risk patients is still being explored, with expectations to break even by 2028. This news has had a certain impact on market confidence. Source: Wall Street Insight There are no other significant news recently. The vaccine industry is facing policy changes and market challenges